An AI Model May Predict Elevated Pancreatic Cancer Risk Using Electronic Health Records
NEW ORLEANS – An artificial intelligence (AI) model trained using sequential health information derived from electronic health records identified...
Search/Filter
Loading...
Investigational Therapy Pyrotinib with Chemotherapy May Improve Outcomes in Patients with Pretreated HER2-positive Breast Cancer
SAN ANTONIO – Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had...
Breast Cancer Patients with Estrogen Receptor Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib
Mutations were detected via circulating tumor DNA before disease progression in patients treated with an aromatase inhibitor/palbociclib for hormone...
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Patients With Breast Cancer
Concurrent treatment with PI3K pathway inhibitors may benefit at-risk patients SAN ANTONIO – Uterine cancers that developed in patients...
Black and White Women Who Received Neoadjuvant Therapy Were Equally Likely to Have Pathologic Complete Response
Tumor biology, not race, was a more significant factor in predicting response to clinical trial treatment SAN ANTONIO – Analysis...
Black Women are More Likely to Develop Lymphedema Following Breast Cancer Treatment than White Women
SAN ANTONIO – Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was...
Elacestrant May Improve Outcomes for Patients Whose Metastatic Breast Cancers Progressed on Prior Endocrine Therapy
Elacestrant is the first oral selective estrogen receptor degrader to show clinical benefit over standard of care in a...
Single-cell Spatial Analysis May Help Predict Response to Neoadjuvant Immunotherapy in Triple-negative Breast Cancer
Imaging mass cytometry was feasible in a large clinical trial of atezolizumab in combination with chemotherapy SAN ANTONIO –...
Using Genomics to Match Treatments Improved Outcomes for Certain Patients With Metastatic Breast Cancer
The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) was highly predictive of the benefits of targeted therapies...
A Peptide-drug Conjugate that Targets the Acidic Environment of Cancer Cells May Improve the Efficacy of Immunotherapy
PHILADELPHIA – A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint...